GlassScriptPhysician profile
Joseph P Deluca
NPI 1629090071
$11,788.97
in general payments reported to CMS, 2019-2025
66 companies · $1,303 in 2025
The $1,303 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,567 · 2020: $1,932 · 2021: $570 · 2022: $1,412 · 2023: $2,327 · 2024: $1,677 · 2025: $1,303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,248 · Education: $59.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,247.55 |
| Education | $59.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,332.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,273.69 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $1,187.74 | 2021-2025 | |
| Pfizer INC. | $890.64 | 2019-2025 | |
| Amarin Pharma, INC. | $867.33 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $697.43 | 2019-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $658.13 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $460.94 | 2019-2025 | Jardiance, Mounjaro, Trulicity |
| Allergan, INC. | $358.48 | 2019-2020 | |
| Amgen INC. | $330.95 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $280.50 | 2019-2025 | Gardasil 9, Capvaxive, Verquvo |
| Exact Sciences Corporation | $277.88 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $257.01 | 2019-2025 | Trintellix, Gattex |
| Otsuka America Pharmaceutical, INC. | $256.94 | 2023-2025 | Rexulti, Nuedexta |
| Astrazeneca Pharmaceuticals LP | $251.93 | 2019-2024 | Flumist Quadrivalent, Breztri, Airsupra |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Deluca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.